Full Breakdown
Life Biosciences Begins First Human Trial of ER-100 Gene Therapy for Glaucoma
6/11/2026, 1:35:56 AM
First Dose Administered
Life Biosciences announced the inaugural ER-100 dose was given to a participant. The viral vector delivers three reprogramming genes to retinal ganglion cells, and an antibiotic-controlled switch regulates expression. FDA approval was granted on Jan. 15.
Reprogramming Aims to Revert Cells
Reprogramming aims to revert aged cells to a youthful state. ER-100 uses three Yamanaka factors. In 2020, David Sinclair showed that activating these genes restored optic-nerve connections and vision in mice. Life Biosciences reports rodent and primate studies found no serious safety signals.
Trial Design and Cohort
The trial will enroll up to 18 adults: twelve with open-angle glaucoma receive a single ER-100 injection, followed by six with NAION. An antibiotic regimen toggles gene activity, permitting dose adjustments. Participants will be followed for at least five years, with safety as primary endpoint and visual function secondary.
Official Statements
Life Biosciences says ER-100 does not edit the genome and that the antibiotic-controlled switch offers control; Sharon Rosenzweig-Lipson reports no serious safety signals in animal studies. David Sinclair calls the trial a pivotal moment for aging biology, noting that epigenetic loss drives aging and will test if restoring epigenetic information can ameliorate disease.
Criticism & Safety
Reprogramming could trigger oncogenic transformation. Matt Kaeberlein notes the technology is early and carries a risk of side effects. Paul Knoepfler argues ER-100 will not lower intra-ocular pressure in glaucoma and cautions that rejuvenation may be short-lived. Critics say anti-aging claims are overstated without robust safety data.
Key Data Points
ER-100 activates three reprogramming genes per eye. The trial will treat up to 18 participants (12 OAG, 6 NAION). Rodent and primate studies showed neuronal regeneration and no serious adverse events.
Unresolved Issues
Efficacy remains untested; the trial will first report safety, leaving open questions about vision improvement and intra-ocular pressure reduction. Optimal dosing, duration of gene expression, and long-term durability are undefined, and independent verification of animal safety is lacking.
Verbatim Quotes
"Reprogramming has a big upside if it can be used safely in people," — Matt Kaeberlein, Optispan
"This is an important moment for Life Bio and for the field of aging biology," — David Sinclair, Life Biosciences
"One challenge is that ER-100, even under ideal reprogramming conditions (which no one knows in the human eye), will not lower the eye pressure of glaucoma." — Paul Knoepfler, UC Davis
"We just have to keep it real. A lot can go wrong." — Paul Knoepfler, UC Davis
Future Steps
The trial will continue enrolling participants and monitor safety for at least five years. Interim safety results are expected within a year, guiding potential expansion, longer-term visual assessments, and regulatory considerations.
